EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Urology

• Publication date

  2011-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eururo.2011.01.025PMID 21315502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone.

  2016cited by this paper
• Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.

  2013cited by this paper
• Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients.

  2013cited by this paper
• Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes.

  2012cited by this paper
• Rational indication for docetaxel rechallenge in metastatic castration‐resistant prostate cancer

  2012cited by this paper
• Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors.

  2012cited by this paper
• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Salvage radiotherapy after prostatectomy - what is the best time to treat?

  2012cited by this paper
• Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.

  2012cited by this paper
• Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.

  2012cited by this paper
• Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy.

  2012cited by this paper
• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

  2012cited by this paper
• Intermittent androgen suppression for rising PSA level after radiotherapy.

  2012cited by this paper
• Prostate-Specific Antigen Velocity Versus Prostate-Specific Antigen Doubling Time for Prediction of 11C Choline PET/CT in Prostate Cancer Patients With Biochemical Failure After Radical Prostatectomy

  2012cited by this paper
• A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.

  2011cited by this paper
• Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer.

  2011cited by this paper
• 前立腺癌に関するEAUガイドライン パートII:進行性再発性および性腺摘除抵抗性前立腺癌の治療

  2011cited by this paper
• Commentary on "Sipuleucel-T immunotherapy for castration-resistant prostate cancer". Kantoff PW, Higano CS, Shore ND, Berger

  2011cited by this paper
• Corrigendum to "Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer" [Eur Urol 2010;58:803-15].

  2011cited by this paper
• The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.

  2011cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011cited by this paper
• 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer

  2010cited by this paper
• The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

  2010cited by this paper
• Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone‐releasing hormone therapy: prognostic significance?

  2010cited by this paper
• Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice.

  2010cited by this paper
• Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy

  2010cited by this paper
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

  2010cited by this paper
• Role of targeted therapy in the treatment of advanced prostate cancer

  2010cited by this paper
• Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

  2010cited by this paper
• Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

  2010cited by this paper
• Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection.

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Castration-Resistant Prostate Cancer

  2010cited by this paper
• Implications of bone metastases and the benefits of bone-targeted therapy.

  2010cited by this paper
• Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology

  2010cited by this paper
• Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study

  2010cited by this paper
• Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC).

  2010cited by this paper
• Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

  2010cited by this paper
• Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy.

  2010cited by this paper
• Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.

  2010cited by this paper
• A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer.

  2010cited by this paper
• Metabolic sequelae associated with androgen deprivation therapy for prostate cancer

  2010cited by this paper
• Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography.

  2010cited by this paper
• A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma

  2010cited by this paper
• Is the Roach formula predictive for biochemical outcome in prostate cancer patients with minimal residual disease undergoing local radiotherapy after radical prostatectomy?

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer.

  2010cited by this paper
• Testosterone measurement in patients with prostate cancer.

  2010cited by this paper
• Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer

  2009cited by this paper
• [EAU guidelines on prostate cancer].

  2009cited by this paper
• Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

  2009cited by this paper
• Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto).

  2009cited by this paper
• Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death.

  2009cited by this paper
• Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer

  2009cited by this paper
• Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.

  2009cited by this paper
• Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

  2009cited by this paper
• Role of androgen deprivation therapy for node-positive prostate cancer.

  2009cited by this paper
• Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging

  2009cited by this paper
• Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.

  2009cited by this paper
• Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument.

  2009cited by this paper
• Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.

  2009cited by this paper
• Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.

  2009cited by this paper
• Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument.

  2009cited by this paper
• Metabolic complications of androgen deprivation therapy for prostate cancer.

  2009cited by this paper
• Die radikale Salvageprostatektomie

  2008cited by this paper
• Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure.

  2008cited by this paper
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008cited by this paper
• Salvage prostate cryoablation: initial results from the cryo on-line data registry.

  2008cited by this paper
• Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

  2008cited by this paper
• Treatment failure after primary and salvage therapy for prostate cancer

  2008cited by this paper
• Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer

  2008cited by this paper
• Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).

  2008cited by this paper
• The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

  2008cited by this paper
• Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

  2008cited by this paper
• Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.

  2007cited by this paper
• Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

  2007cited by this paper
• Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

  2007cited by this paper
• The role of intermittent androgen deprivation in prostate cancer

  2007cited by this paper
• Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

  2006cited by this paper
• Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

  2006cited by this paper
• Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.

  2006cited by this paper
• Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

  2006cited by this paper
• Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.

  2006cited by this paper
• Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer

  2006cited by this paper
• Radikale Salvageprostatektomie bei lokalem Prostatakarzinomrezidiv nach Strahlentherapie

  2006cited by this paper
• [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].

  2006cited by this paper
• Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.

  2005cited by this paper
• Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease

  2005cited by this paper
• Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy

  2005cited by this paper
• Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

  2004cited by this paper
• Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy.

  2004cited by this paper
• Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  2004cited by this paper

• PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone‐Sensitive Prostate Cancer (mHSPC) in Real‐World Analyses?

  2025cites this paper
• Preclinical Evaluation Study of 68Ga-Labeled PSMA-Targeted Dimer Probe

  2025cites this paper
• Evaluation of optimal timing and therapeutic efficacy of radium-223 therapy for metastatic castration-resistant prostate cancer: a multicenter collaborative study.

  2025cites this paper
• Targeted and immunotherapeutic strategies for castration-resistant prostate cancer: emerging strategies, challenges, and future directions

  2025cites this paper
• Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort

  2025cites this paper
• Complete Response Case of Metastatic Hormone-Sensitive Prostate Cancer Treated With Triplet Therapy (Androgen Deprivation Therapy + Docetaxel + Darolutamide)

  2025cites this paper
• To eat or not to eat: a critical review on the role of autophagy in prostate carcinogenesis and prostate cancer therapeutics

  2024cites this paper
• Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction

  2024cites this paper
• Update on PSMA-based Prostate Cancer Imaging.

  2024cites this paper
• Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world

  2024cites this paper
• Flavones: The Apoptosis in Prostate Cancer of Three Flavones Selected as Therapeutic Candidate Models

  2023cites this paper
• Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis

  2023cites this paper
• Quantitative ultrasound of the calcaneus (QUS): A valuable tool in the identification of patients with non-metastatic prostate cancer requiring screening for osteoporosis

  2023cites this paper
• Effects of androgen deprivation therapy on metabolic markers and bioelectrical impedance analyze in prostate cancer patients.

  2022cites this paper
• SOX9 and HMGB3 co‐operatively transactivate NANOG and promote prostate cancer progression

  2022cites this paper
• Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database

  2022cites this paper
• Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)

  2022cites this paper
• Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer.

  2022cites this paper
• The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment.

  2022cites this paper
• The impact of androgen deprivation therapy on the lipid profile in patients with prostate carcinoma

  2022cites this paper
• Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines

  2021influential citation
• Real world treatment utilization patterns in patients with castration-resistant prostate cancer

  2021cites this paper
• Does Protocol Make a Difference? Comparison of Two Prostate Cancer Active Surveillance Cohorts: A Non–protocol-based Follow-up and a Protocol-based Contemporary Follow-up

  2021cites this paper
• 18F-Choline, 68Ga-PSMA-11 and 18F-FDG PET/CT in Treatment Response Evaluation: Prostate Cancer

  2021cites this paper
• Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer

  2021cites this paper
• Advances in Magnetic Nanoparticle-Driven Delivery of Gene Therapies towards Prostate Cancer

  2021cites this paper
• Sex hormones abnormalities in non-alcoholic fatty liver disease: pathophysiological and clinical implications

  2021cites this paper
• Impact of the Noise Penalty Factor on Quantification in Bayesian Penalized Likelihood (Q.Clear) Reconstructions of 68Ga-PSMA PET/CT Scans

  2021cites this paper
• Use of miR-145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer

  2021cites this paper
• Epigenetic Editing in Prostate Cancer: Challenges and Opportunities

  2021cites this paper
• Factors determining the efficacy of radiotherapy for prostate cancer

  2021cites this paper
• Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy

  2021cites this paper
• Prostate cancer follow-up costs in Germany from 2000 to 2015

  2021cites this paper
• Comparison of Regularized Reconstruction and Ordered Subset Expectation Maximization Reconstruction in the Diagnostics of Prostate Cancer Using Digital Time-of-Flight 68Ga-PSMA-11 PET/CT Imaging

  2021cites this paper
• Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry

  2020cites this paper
• Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: A post-hoc analysis of RTOG 9601 trial data.

  2020cites this paper
• Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice

  2020cites this paper
• 11-Oxygenated androgens in health and disease

  2020cites this paper
• Up‐regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence

  2020cites this paper
• Stroma transcriptomic and proteomic profile of prostate cancer metastasis xenograft models reveals conservation of bone microenvironment signatures

  2020cites this paper
• Early Catheter Removal After Robot-assisted Radical Prostatectomy: Results from a Prospective Single-institutional Randomized Trial (Ripreca Study).

  2020cites this paper
• Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry.

  2020cites this paper
• Progesterone Receptor Expression in the Benign Prostatic Hyperplasia and Prostate Cancer Tissues, Relation with Transcription, Growth Factors, Hormone Reception and Components of the AKT/mTOR Signaling Pathway

  2020cites this paper
• Shortening the acquisition time of whole-body MRI: 3D T1 gradient echo Dixon vs fast spin echo for metastatic screening in prostate cancer

  2020cites this paper
• Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods

  2020cites this paper
• Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer.

  2020cites this paper
• Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy

  2020cites this paper
• Gold nanoparticle clusters for the investigation of therapeutic efficiency against prostate cancer under near-infrared irradiation

  2020cites this paper
• Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone

  2020cites this paper
• A predictive model for prostate cancer incorporating PSA molecular forms and age

  2020cites this paper
• Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer.

  2020cites this paper
• The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.

  2020cites this paper
• Oligometastatic prostate cancer: diagnosis and preliminary results of radiation therapy

  2020cites this paper
• Radiation Therapy for Benign Disease: Arteriovenous Malformations, Desmoid Tumor, Dupuytren Contracture, Graves Ophthalmopathy, Gynecomastia, Heterotopic Ossification, Histiocytosis.

  2020cites this paper
• Salvage Re-irradiation Therapy After Loco-regional Failure for Radiotherapy

  2020cites this paper
• Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone.

  2020cites this paper
• Salvage Robot-Assisted Radical Prostatectomy for Recurrent Localized Prostate Cancer after Radiation Therapy

  2020cites this paper
• Silica‐Based Nanoparticles as Drug Delivery Vehicles for Prostate Cancer Treatment

  2020cites this paper
• Доцетаксел и бисфосфонаты при гормоночувствительном раке предстательной железы

  2020cites this paper
• The role of adrenal derived androgens in castration resistant prostate cancer.

  2020cites this paper
• Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer

  2020cites this paper
• Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR)

  2020cites this paper
• Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer

  2020cites this paper
• Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer

  2020cites this paper
• Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database.

  2020cites this paper
• Nanomaterial based aptasensing of prostate specific antigen (PSA): Recent progress and challenges in efficient diagnosis of prostate cancer using biomedicine.

  2020cites this paper
• The Effect of Exercise on Body Composition and Physical Performance in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (ADT): A Narrative Synthesis.

  2020cites this paper
• Evaluation of Gleason Grade Group 5 in a Contemporary Prostate Cancer Grading System and Literature Review.

  2020cites this paper
• Small cell carcinoma of the bladder with coexisting prostate adenocarcinoma: two cases report and literature review

  2020cites this paper
• Single‐fraction image‐guided robotic radiosurgery efficiently controls local prostate cancer recurrence after radical prostatectomy

  2020cites this paper
• Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate Cancer.

  2020cites this paper
• Salvage Pelvic Lymph Node Dissection and Current State of Imaging for Recurrent Prostate Cancer: Does a Standard Exist?

  2020cites this paper
• PET/CT in der Strahlentherapie

  2020cites this paper
• EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer

  2020cites this paper
• Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer

  2020cites this paper
• Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer

  2020cites this paper
• Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence

  2020cites this paper
• Robot-assisted radical prostatectomy with clipless intrafascial neurovascular bundle-sparing approach: surgical technique and one-year functional and oncologic outcomes

  2020cites this paper
• Downregulation of circular RNA hsa_circ_0000735 boosts prostate cancer sensitivity to docetaxel via sponging miR-7

  2020cites this paper
• WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation

  2020cites this paper
• Response Assessment and Follow-Up by Imaging in GU Tumours

  2020cites this paper
• Prostatakarzinom beim geriatrischen Patienten

  2020cites this paper
• Adipocytes protect fibroblasts from radiation-induced damage by adiponectin secretion

  2020cites this paper
• Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance

  2020cites this paper
• Coexpression Analysis of the EZH2 Gene Using The Cancer Genome Atlas and Oncomine Databases Identifies Coexpressed Genes Involved in Biological Networks in Breast Cancer, Glioblastoma, and Prostate Cancer

  2020cites this paper
• Novel PET imaging methods for prostate cancer

  2020cites this paper
• Molecular mechanisms and clinical management of cancer bone metastasis

  2020cites this paper
• Accuracy of 68Ga-PSMA-11 PET/CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of prostate cancer.

  2020cites this paper
• A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy

  2020cites this paper
• Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers

  2020cites this paper
• Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance

  2020cites this paper
• The Effect of Prostate Cancer Radiotherapy on Testosterone Level: A Systematic Review and Meta-Analysis.

  2020cites this paper
• Harnessing the potential of multimodal radiotherapy in prostate cancer

  2020cites this paper
• Therapie bei isoliertem PSA-Anstieg

  2020cites this paper
• The Role of Exenterative Surgery in Advanced Urological Neoplasms.

  2020cites this paper
• Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?

  2020cites this paper
• p2PSA for predicting biochemical recurrence of prostate cancer earlier than total prostate-specific antigen after radical prostatectomy: an observational prospective cohort study.

  2019cites this paper
• Qualitative study of patients with metastatic prostate cancer to adherence of hormone therapy.

  2019cites this paper
• Comparison of bone lesion distribution between prostate cancer and multiple myeloma with whole-body MRI.

  2019cites this paper
• Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol

  2019cites this paper